Secondgeneration Antipsychotics: Metabolic Syndrome

1
Second-generation AntipsychoticsMetabolic
Syndrome

• Recent reports by the FDA, ADA, APA, AACE, and
  NAASO have raised concerns regarding obesity,
  diabetes, and dyslipidemia as adverse effects of
  atypical antipsychotic agents1
• In addition, the metabolic syndrome appears to be
  more common in patients with schizophrenia and
  bipolar disorder
• Monitoring is now recommended1,2

AACE American Association of Clinical
Endocrinologists NAASO North American
Association for the Study of Obesity 1. American
Diabetes Association. Diabetes Care.
200427596-601. 2. Buse JB. J Clin Psychiatry.
200263(suppl 4)37-41.